| Date Filed | Type | Description |
| 05/11/2020 |
GN
| Akorn Provides First Quarter 2020 Results |
| 12/16/2019 |
GN
| Akorn Announces Extension of Standstill Agreement |
| 11/05/2019 |
GN
| Akorn to Present at the Credit Suisse Healthcare Conference |
| 10/31/2019 |
GN
| Akorn Provides Preliminary Third Quarter 2019 Results |
| 08/26/2019 |
GN
| Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15% |
| 07/11/2019 |
GN
| Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call |
| 06/28/2019 |
GN
| Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5% |
| 05/20/2019 |
GN
| Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1% |
| 05/20/2019 |
GN
| Akorn to Present at the RBC Capital Markets Healthcare Conference |
| 05/07/2019 |
GN
| Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance |
| 04/22/2019 |
GN
| FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC |
| 04/19/2019 |
GN
| Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI |
| 04/18/2019 |
GN
| Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5% |
| 04/18/2019 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX |